Vilobelimab is under clinical development by InflaRx and currently in Phase III for Pyoderma Gangrenosum. According to GlobalData, Phase III drugs for Pyoderma Gangrenosum does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Vilobelimab LoA Report. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vilobelimab overview

Vilobelimab (Gohibic) is an immunosuppressive agent. It is formulated as solution for intravenous infusion route of administration. Gohibic is indicated for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).

Vilobelimab (IFX-1) is under development for the treatment of COVID-19 pneumonia, SARS-CoV-2 induced septic acute respiratory distress syndrome (ARDS) and ulcerative pyoderma gangrenosum. It is administered through intravenous route in the form of solution. The drug candidate is a humanized monoclonal antibody targeting the complement activation product C5a.

The drug candidate was under development for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), anti-neutrophil cytoplasmic antibody-associated vasculitis, septic organ dysfunction, systemic inflammatory response syndrome (SIRS) induced organ dysfunction (sepsis, septic shock, multiple organ dysfunction, inflammation), acute lung injury, community-acquired pneumonia, hidradenitis suppurativa, chronic Inflammation and advanced or metastatic cutaneous squamous cell carcinoma (cSCC).

InflaRx overview

InflaRx is a clinical-stage biopharmaceutical company that develops therapies in the field of acute and chronic inflammation. Its pipeline products include INF904, IFX002 and vilobelimab among others. The company offers the development of monoclonal antibodies targeting activation products of the complement system for application in threatening inflammatory diseases and others drug indications. InflaRx operates in various research and development programs in the life science sectors. The company offers antibodies that are able to fulfill requirements determined by InflaRx for the generation of suitable drug candidates. It offers research services through collaboration with universities and biotech companies. InflaRx is headquartered in Jena, Germany.

For a complete picture of Vilobelimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.